June 12, 2006
27th Goldman Sachs Annual Global Healthcare Conference

Bayer antithrombosis drug BAY 59-7939: Compelling data from recent phase II clinical studies support decision to proceed with phase III programs

Phase III programs in two chronic indications / Once-daily dosing in the phase III programs for stroke prevention in atrial fibrillation and treatment of venous thromboembolism

Leverkusen / Laguna Niguel, USA - Compelling data from recent phase II clinical studies support the decision to proceed with phase III programs for Bayer HealthCare's antithrombosis drug BAY 59-7939 in two chronic indications. The compound with the active ingredient rivaroxaban will be tested in the chronic indications stroke prevention in atrial fibrillation (SPAF) and treatment of venous thromboembolism (VTE) in a once-daily dose regimen. This important milestone for BHC's pipeline was announced by Arthur J. Higgins, Chairman of BHC's Executive Committee, at the 27th Annual Goldman Sachs Healthcare Conference in Laguna Niguel, CA.

Furthermore, Higgins announced that four pipeline projects (one in cancer; three in cardiovascular), one more than originally planned, have already reached Phase II, and seven new development candidates are scheduled to undergo clinical testing in humans in 2006.

Bayer HealthCare and Ortho-McNeil Pharmaceutical Inc., a Johnson&Johnson company, who are jointly developing and marketing the antithrombosis drug, have conducted the largest ever Phase II dose-finding program with more than 1,100 patients for VTE therapy and stroke prevention in atrial fibrillation. "The phase II data are impressive and underline our confidence in rivaroxaban," said Arthur J. Higgins. "There is currently a pressing medical need for an oral, easy-to-administer agent that offers predictable anticoagulation, without the need for routine monitoring or dose adjustment. We believe that oral, once-daily rivaroxaban will change the paradigm of patient treatment, enabling more patients to benefit from more convenient and safer anticoagulation."

Bayer HealthCare and Ortho-McNeil Pharmaceutical have initiated discussions with regulatory authorities on the phase III clinical development program in both of these important indications. Based on current plans the first regulatory filing in a chronic indication is anticipated in 2009.

"All the doses of rivaroxaban studied provided effective anticoagulation, with a low incidence of recurrent VTE in both studies in patients with symptomatic deep vein thrombosis. Moreover, the efficacy and safety of all doses of rivaroxaban were similar to the standard therapy - typically a heparin followed by warfarin. These data are excellent," explained Professor Harry Büller of the Academic Medical Center, Amsterdam, Netherlands and the principal investigator of EINSTEIN-DVT - the study that investigated once-daily rivaroxaban doses of 20, 30 and 40 mg.

ODIXa-DVT, the study led by Professor Giancarlo Agnelli, University of Perugia, Italy - investigated rivaroxaban in dosages of 10, 20 and 30 mg twice daily and 40 mg once-daily. Commenting on the safety in both of these studies, Professor Agnelli said: "Importantly, rivaroxaban showed a favourable safety profile with low rates of any bleeding or adverse events, and no signal for liver toxicity. No study arm was stopped and all the doses tested, irrespective of the dosing regimen, were considered safe and effective in this setting."

Together, ODIXa-DVT and EINSTEIN-DVT enrolled 1156 patients with acute, symptomatic DVT. Both studies assessed a wide range of daily doses of rivaroxaban against the active control - standard therapy of parenterally-administered heparin, such as a low molecular weight heparin (e.g. enoxaparin) or unfractionated heparin, followed by warfarin for up to 12 weeks.

The full data sets for both studies in the phase II dose-finding program will be presented on September, 5 2006 at the upcoming joint World Congress of Cardiology and European Society of Cardiology congress in Barcelona, Spain.

Rivaroxaban is already in phase III clinical development for VTE prevention after major elective orthopaedic surgery. The RECORD (REgulation of Coagulation in major Orthopaedic surgery reducing the Risk of DVT and PE) study program began in December 2005 and recruitment is on track and progressing well. At present Bayer HealthCare is on track for filing for market authorization in late 2007.

About rivaroxaban (BAY 59-7939)
Rivaroxaban is a novel, oral, direct Factor Xa inhibitor that reduces the risk of life threatening thromboembolic events. Factor Xa is a protease (the target enzyme) that acts at the pivotal point in the coagulation cascade (the process that leads to clot formation).

Present published results show that rivaroxaban offers predictable anticoagulation across a wide range of parameters, which strongly suggests that coagulation monitoring will not be required. In addition, data also show that rivaroxaban does not interact with a wide variety of drugs that are commonly given concomitant with an anticoagulant.

Rivaroxaban has the potential to offer a simple and convenient, once-daily dosing regimen in the primary prevention of thromboembolic events after major orthopaedic surgery and in patients with atrial fibrillation, and for VTE treatment and long-term secondary prevention. As an oral drug, rivaroxaban will clearly be useful in both the acute and chronic setting, and would be particularly convenient for patients who need continued anticoagulation at home, after discharge from hospital.

Bayer HealthCare
Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the health care and medical products industry based in Leverkusen/Germany. In 2005, the Bayer HealthCare subgroup generated sales amounting to some 9.4 billion Euro. Bayer HealthCare employed 33.800 people worldwide in 2005.

The company combines the global activities of the divisions Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. Since January 1, 2006 the new Pharmaceutical Division consists of the former Biological Products and Pharmaceutical Division and now comprises three business units: Hematology/Cardiology, Oncology and Primary Care.

Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.

Forward-looking statements<br/>
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F).The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.